Customized Services And OEM/ODM Perspective | Flexible Customization Capabilities Of Menghini Liver Biopsy Needle And Manners Technology’s Supply‑Chain Value
May 12, 2026
In the global minimally invasive interventional device market, competition for standardized off‑the‑shelf Menghini liver biopsy needles has become increasingly intense. Custom parameter adjustment, private‑label OEM/ODM manufacturing, and integrated OEM/ODM services have emerged as key differentiators for manufacturers to break through market saturation. Backed by an in‑house material supply chain, five‑axis precision machining capabilities, and a mature quality management system, Manners Technology delivers end‑to‑end flexible customization of Menghini needles - covering specifications, structure, packaging, sterilization, and branding - based on clients' clinical requirements, target‑market regulatory constraints, and brand positioning. This positions the company as a core supply‑chain partner for domestic and international medical‑device brands, trading companies, and healthcare institutions.
Clinical application of Menghini liver biopsy needles exhibits highly scenario‑specific variations: puncture depths differ between adult and pediatric patients; outer diameter and wall‑thickness requirements vary for obese and emaciated patients; and puncture approaches as well as negative‑pressure device interfaces differ across hospitals. One of Manners Technology's core strengths lies in its ability to tailor critical parameters - including needle length, outer diameter, inner diameter, tip angle, negative‑pressure interface specifications, and hub structure - according to clients' 2D/3D drawings or clinical requirements, enabling one‑to‑one customized development. Whether it is an ultra‑fine pediatric‑specific variant, an extended‑length model for obese patients, or a custom interface for a specific negative‑pressure device, the company can rapidly complete sampling, verification, and mass production, significantly shortening clients' new‑product R&D cycles.
In the OEM/ODM segment, Manners Technology provides end‑to‑end white‑label, private‑label, and brand‑customization services, including exclusive packaging design, brand logo silk‑screen printing, customized sterilization protocols, and multilingual instruction manual compilation. Clients can launch their own branded Menghini liver biopsy needles without establishing in‑house manufacturing facilities or production lines. Currently, numerous small‑ and medium‑sized global medical‑device brands, regional distributors, and overseas healthcare institutions partner with compliant Chinese manufacturers to reduce factory‑building costs, accelerate time‑to‑market, and enhance cost‑performance ratios. Manners' dual‑system certifications, precision manufacturing expertise, and regulatory compliance support perfectly align with such client demands.
From a supply‑chain perspective, Manners achieves full‑chain in‑house control spanning raw‑material procurement, tube drawing, laser cutting, grinding and polishing, cleaning and sterilization, clean‑room packaging, and logistics delivery. By eliminating intermediate links, the company ensures stable lead times and cost predictability. Compared with pure trading enterprises or small assembly‑only factories, it delivers superior quality control and order fulfillment capabilities, making it particularly suitable for large‑volume international orders, government public‑health procurements, and hospital group purchasing programs.
As the global healthcare market undergoes refined specialization, European and American brands are gradually divesting low‑value‑added production activities and shifting the manufacturing, customization, and OEM production of basic biopsy instruments such as Menghini needles to the Asia‑Pacific region. Leveraging its three core advantages in technology, regulatory compliance, and customization, Manners Technology undertakes global orders while driving the export of Chinese technologies and standards. The company is evolving from a pure OEM manufacturer into a key global supplier, advancing the transition from "Made in China" to "Intelligently Made in China".
